{
  "docId": "019de074-a9ac-701c-b608-a7d685a23a86",
  "docSlug": "61bfab17df32945e4c5e1e9eb8b915b7",
  "documentTitle": "argenx SE | Investor Presentation Deck | 22 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 22,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Includes a biological mechanism diagram on the left and a clinical trial timeline/roadmap on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a9ac-701c-b608-a7d685a23a86/16",
  "deckHref": "/decks/019de074-a9ac-701c-b608-a7d685a23a86",
  "deckJsonHref": "/decks/019de074-a9ac-701c-b608-a7d685a23a86.json",
  "deckAnchorHref": "/decks/019de074-a9ac-701c-b608-a7d685a23a86#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.175,
        "x": 0.825,
        "y": 0
      },
      "kind": "callout",
      "text": "clinical Broaden immunology pipeline",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e36fdc52-0528-466c-82f9-bba32e24cdff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.7,
        "x": 0.29,
        "y": 0.28
      },
      "kind": "diagram",
      "text": "First-in-Human Phase 1 Healthy Volunteer Study timeline",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "974e42c9-144b-42b3-9d0c-7e113f92689c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "image",
      "text": "Biological mechanism diagram showing MuSK, LRP4, and AChR interaction",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c65e508a-4b94-4560-b9dd-55a41617a3f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.23,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "First-in-patient trial in CMS to serve as proof of biology. Translational work ongoing in amyotrophic lateral sclerosis (ALS)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3ce031a-b8d5-4aba-ad12-4b690a7c2fdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2426e7a2-5b71-459a-a8bd-125c5bcc6396",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "97bea28a-6417-499c-a2be-83919bf07c42",
      "evidence": "The slide depicts a clinical development roadmap with sequential study phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 7,
      "beatId": "5f17aabc-eb4c-4e3b-b30e-070b7656292a",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "How",
      "beatSlug": "golden-circle-how",
      "evidence": "The presentation finally explains 'how' (pipeline and growth potential)",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "9faf6166-e0e0-46b6-9e29-f48774efbe4d",
      "evidence": "The presentation uses a golden circle framework to explain the company's mission and growth potential",
      "position": 0,
      "objective": "Explain the company's mission and growth potential",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}